amphetamine has been researched along with risperidone in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 5 (15.63) | 18.2507 |
| 2000's | 13 (40.63) | 29.6817 |
| 2010's | 12 (37.50) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Awouters, FH; Megens, AA; Niemegeers, CJ | 1 |
| Awouters, F; Janssen, PA; Meert, TF; Megens, AA; Niemegeers, CJ; Schellekens, KH | 1 |
| Awouters, FH; Janssen, PA | 1 |
| Dashevsky, B; Frank, RA; Grocki, S; Kehne, JH; Schmidt, CJ; Sorensen, SM; Tsibulsky, V | 1 |
| Adler, CM; Breier, A; Elman, I; Malhotra, AK; Pickar, D; Su, TP; Weisenfeld, NI | 1 |
| Fourie, H; Jha, A | 1 |
| Kraemer, T; Kratzsch, C; Maurer, HH; Peters, FT; Weber, AA | 1 |
| Baba, A; Hashimoto, H; Shintani, N; Tanaka, K | 1 |
| Avena, N; Fisher, H; Halladay, AK; Kita, T; Nakashima, T; Wagner, GC | 1 |
| Ahlbrand, R; Burr, J; Coolen, LM; Hayes, S; Herman, JP; Logue, A; McNamara, RK; Ostrander, MM; Pritchard, LM; Richtand, NM; Taylor, B; Welge, JA | 1 |
| Alimohamad, H; Mouyal, J; Rajakumar, N; Rushlow, WJ; Sutton, L | 1 |
| Gruber, SH; Mathé, AA; Nomikos, GG | 1 |
| Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I | 1 |
| Crabbe, JC; Philibin, SD; Porter, JH; Vunck, SA; Walentiny, DM | 1 |
| Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
| Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI | 1 |
| Azar, MR; Geyer, MA; Gold, L; Marston, HM; Martin, FD; Meltzer, LT; Moore, CL; Serpa, KA; Shahid, M; Wong, EH; Young, JW | 1 |
| Casti, P; Casu, G; Marchese, G; Pani, L; Spada, GP | 1 |
| Ahlbrand, R; Bronson, SL; Horn, P; McNamara, RK; Richtand, NM; Stanford, K | 1 |
| Anderson, GW; Einat, H; Flaisher-Grinberg, S; Hannah-Poquette, C; Meinerding, TM; Wang, J | 1 |
| Terry, AV; Wilson, CA | 1 |
| Abdoli, N; Aghaei, A; Bajoghli, H; Brand, S; Farnia, V; Juibari, TA; Shakeri, J; Tatari, F; Yazdchi, K | 1 |
| El-Sayed El-Sayad, M; El-Sayed El-Sisi, A; Osman, EY; Sayed Ramadan, E; Sokkar, SS | 1 |
| Bardgett, ME; Brown, CJ; Lee Stubbeman, B; Yates, JR | 1 |
| Ahnaou, A; Drinkenburg, WHIM; Huysmans, H; Van de Casteele, T | 1 |
| Ahrens, PS; Gallagher, M; Koh, MT | 1 |
| Baltes Thompson, EC; Bardgett, ME; Cox, B; Crane, C; Downnen, T | 1 |
| Baltes Thompson, EC; Bardgett, ME; Crane, C; Downnen, T; Muncie, B; Pauly, JR; Steffen, SA; Yates, JR | 1 |
1 review(s) available for amphetamine and risperidone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for amphetamine and risperidone
| Article | Year |
|---|---|
Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders.
Topics: Adult; Amphetamine; Antipsychotic Agents; Clozapine; Dopamine Antagonists; Dopamine Uptake Inhibitors; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neostriatum; Psychotic Disorders; Raclopride; Risperidone; Salicylamides; Tomography, Emission-Computed | 1999 |
Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis.
Topics: Adolescent; Adult; Amphetamine; Antipsychotic Agents; Aripiprazole; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychoses, Substance-Induced; Quinolones; Risperidone; Symptom Assessment; Treatment Outcome; Young Adult | 2014 |
29 other study(ies) available for amphetamine and risperidone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Dose-Response Relationship, Drug; Drug Interactions; Haloperidol; Isoxazoles; Male; Motor Activity; Piperidines; Pyrimidinones; Rats; Rats, Inbred Strains; Risperidone | 1992 |
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Conditioning, Psychological; Dogs; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Isoxazoles; Male; Motor Activity; Oxazoles; Piperidines; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D2; Risperidone; Serotonin Antagonists | 1988 |
Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Butyrophenones; Dogs; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; In Vitro Techniques; Isoxazoles; Lysergic Acid Diethylamide; Motor Activity; Neostriatum; Oxygen Consumption; Piperidines; Rats; Risperidone; Schizophrenia; Serotonin Antagonists; Species Specificity; Tryptamines | 1994 |
Mixed D2/5-HT2A antagonism of amphetamine-induced facilitation of brain stimulation reward.
Topics: Amphetamine; Animals; Brain; Dose-Response Relationship, Drug; Haloperidol; Male; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin; Reward; Risperidone | 1995 |
Risperidone treatment of amphetamine psychosis.
Topics: Aged; Amphetamine; Antipsychotic Agents; Central Nervous System Stimulants; Female; Humans; Psychoses, Substance-Induced; Risperidone | 1999 |
Negative ion chemical ionization gas chromatography-mass spectrometry and atmospheric pressure chemical ionization liquid chromatography-mass spectrometry of low-dosed and/or polar drugs in plasma.
Topics: Amphetamine; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Central Nervous System Stimulants; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Drug Monitoring; Gas Chromatography-Mass Spectrometry; Humans; Indicators and Reagents; Methamphetamine; Pharmaceutical Preparations; Poisons; Risperidone; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism | 2002 |
[Altered behavioral response to centrally acting drugs in mice lacking PACAP].
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior, Animal; Disease Models, Animal; Fluoxetine; Haloperidol; Mice; Mice, Knockout; Neuropeptides; Pituitary Adenylate Cyclase-Activating Polypeptide; Risperidone | 2003 |
Risperidone reduction of amphetamine-induced self-injurious behavior in mice.
Topics: Amphetamine; Animals; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred BALB C; Motor Activity; Risperidone; Self-Injurious Behavior | 2004 |
Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Circadian Rhythm; Dentate Gyrus; Dopamine Uptake Inhibitors; Excitatory Amino Acid Agonists; Female; Hippocampus; Ibotenic Acid; Motor Activity; Pregnancy; Rats; Rats, Sprague-Dawley; Risperidone | 2006 |
The effects of antipsychotics on beta-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats.
Topics: Adaptor Proteins, Signal Transducing; Amphetamine; Animals; Antipsychotic Agents; Benzazepines; beta Catenin; Blotting, Western; Central Nervous System Stimulants; Clozapine; Cytoskeletal Proteins; Dishevelled Proteins; Dopamine Agonists; Female; Glycogen Synthase Kinase 3; Haloperidol; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Male; Mesencephalon; Phosphoproteins; Quinpirole; Rats; Rats, Sprague-Dawley; Risperidone; Signal Transduction; Trans-Activators; Wnt Proteins; Wnt1 Protein | 2005 |
Effects of acute and subchronic d-amphetamine on ventral striatal concentrations of neurotensin and neuropeptide Y in rats treated with antipsychotic drugs.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Corpus Striatum; Drug Administration Schedule; Drug Interactions; Extracellular Fluid; Haloperidol; Male; Microdialysis; Neuropeptide Y; Neurotensin; Radioimmunoassay; Rats; Rats, Wistar; Risperidone; Time Factors | 2006 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Haloperidol; Head Movements; Male; Mice; Mice, Inbred Strains; Motor Activity; Piperidines; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Urea | 2007 |
A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Discrimination Learning; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Olanzapine; Risperidone | 2008 |
Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
Topics: Amisulpride; Amphetamine; Animals; Antipsychotic Agents; Basal Ganglia; Behavior, Animal; Blood-Brain Barrier; Brain; Clozapine; Conditioning, Psychological; Haloperidol; Male; Models, Animal; Motor Activity; Phencyclidine; Prefrontal Cortex; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, Serotonin; Risperidone; Sulpiride | 2008 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous System Stimulants; Disease Models, Animal; Drug Interactions; Electroencephalography; Evoked Potentials, Auditory; Excitatory Amino Acid Antagonists; Haloperidol; Ketamine; Male; Mice; Mice, Inbred C57BL; Reaction Time; Risperidone; Schizophrenia | 2009 |
Asenapine effects in animal models of psychosis and cognitive function.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Attention; Benzodiazepines; Cognition; Dibenzocycloheptenes; Disease Models, Animal; Dose-Response Relationship, Drug; Heterocyclic Compounds, 4 or More Rings; Male; Olanzapine; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Risperidone | 2009 |
Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Catalepsy; Chemistry, Pharmaceutical; Hyperkinesis; Male; Motor Activity; Rats; Rats, Sprague-Dawley; Reaction Time; Risperidone; Time Factors | 2009 |
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Central Nervous System Stimulants; Disease Models, Animal; Drug Interactions; Female; Isoxazoles; Motor Activity; Paliperidone Palmitate; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Pyrimidines; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Time Factors | 2011 |
Modeling mania: Further validation for Black Swiss mice as model animals.
Topics: Amphetamine; Animals; Animals, Outbred Strains; Behavior, Animal; beta Catenin; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Frontal Lobe; Hippocampus; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred Strains; Risperidone; Species Specificity | 2011 |
Variable maternal stress in rats alters locomotor activity, social behavior, and recognition memory in the adult offspring.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Atomoxetine Hydrochloride; Behavior, Animal; Benzylidene Compounds; Disease Models, Animal; Female; Humans; Male; Maze Learning; Mental Disorders; Motor Activity; Nicotinic Agonists; Pregnancy; Prenatal Exposure Delayed Effects; Propylamines; Pyridines; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Risperidone; Social Behavior; Stress, Physiological | 2013 |
Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Celecoxib; Disease Models, Animal; Drug Therapy, Combination; Fatty Acids, Omega-3; Male; Malondialdehyde; Maze Learning; Rats; Risperidone; Schizophrenia; Tumor Necrosis Factor-alpha | 2016 |
Early-life risperidone enhances locomotor responses to amphetamine during adulthood.
Topics: Amphetamine; Animals; Antipsychotic Agents; Circadian Rhythm; Locomotion; Male; Rats; Risperidone; Time Factors | 2017 |
Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepines; Brain Waves; Central Nervous System Stimulants; Cerebral Cortex; Clozapine; Dizocilpine Maleate; Electroencephalography; Excitatory Amino Acid Antagonists; Male; Nerve Net; Olanzapine; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Risperidone | 2017 |
A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Delusions; Disease Models, Animal; Feeding Behavior; Hallucinations; Ketamine; Learning; Male; Mice, Inbred C57BL; Motor Activity; Olfactory Perception; Risperidone; Schizophrenia; Schizophrenic Psychology | 2018 |
The effects of amphetamine on working memory and locomotor activity in adult rats administered risperidone early in life.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Female; Locomotion; Male; Memory, Short-Term; Rats; Rats, Long-Evans; Risperidone; Time Factors | 2019 |
Chronic risperidone administration leads to greater amphetamine-induced conditioned place preference.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Conditioning, Classical; Dopamine Antagonists; Dopamine Uptake Inhibitors; Drug Administration Schedule; Drug Synergism; Female; Locomotion; Male; Rats; Rats, Long-Evans; Risperidone | 2020 |